Traders sold shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) on strength during trading hours on Thursday. $310.41 million flowed into the stock on the tick-up and $334.72 million flowed out of the stock on the tick-down, for a money net flow of $24.31 million out of the stock. Of all companies tracked, Valeant Pharmaceuticals International had the 0th highest net out-flow for the day. Valeant Pharmaceuticals International traded up $0.55 for the day and closed at $31.09

A number of equities research analysts have commented on the company. Wells Fargo & Co. reissued a “sell” rating and set a $19.50 price target on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Mizuho reissued an “underperform” rating on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Rodman & Renshaw reissued a “buy” rating and set a $90.00 price target on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. TD Securities reissued a “hold” rating and set a $38.00 price target on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Finally, Susquehanna reissued a “hold” rating and set a $105.00 price target on shares of Valeant Pharmaceuticals International in a report on Sunday, May 29th. Six equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $60.32.

The company’s market cap is $10.80 billion. The firm’s 50 day moving average price is $24.87 and its 200 day moving average price is $36.15.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.48 by $0.08. The company had revenue of $2.42 billion for the quarter, compared to analysts’ expectations of $2.47 billion. The business’s revenue for the quarter was down 11.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.14 earnings per share. On average, equities research analysts predict that Valeant Pharmaceuticals International Inc. will post $6.54 EPS for the current fiscal year.

In other Valeant Pharmaceuticals International news, CEO Joseph C. Papa purchased 202,000 shares of the firm’s stock in a transaction on Friday, June 10th. The stock was bought at an average price of $24.48 per share, with a total value of $4,944,960.00. Following the transaction, the chief executive officer now directly owns 2,442,199 shares of the company’s stock, valued at approximately $59,785,031.52. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Argeris N. Karabelas purchased 4,000 shares of the firm’s stock in a transaction on Thursday, August 11th. The stock was acquired at an average cost of $24.65 per share, with a total value of $98,600.00. Following the transaction, the director now directly owns 20,726 shares in the company, valued at $510,895.90. The disclosure for this purchase can be found here.

An institutional investor recently bought a new position in Valeant Pharmaceuticals International stock. State of New Jersey Common Pension Fund D purchased a new stake in shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 20,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,033,000.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.